ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1211

Impact of Change in Biologic Disease Modifying Antirheumatic Drug Therapy on Disease Activity Measures: Findings from a Large Contemporaneous Real-World Longitudinal Database of RA Patients

Zhaohui Su1, Lauren Stevens2, Tom Brecht1, Jessica Paulus1 and Stefan Weiss3, 1OM1, Inc., Boston, MA, 2OM1, Inc., Lexington, KY, 3OM1, Inc., Chapel Hill, NC

Meeting: ACR Convergence 2022

Keywords: Cohort Study, Disease-Modifying Antirheumatic Drugs (Dmards), Epidemiology, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Epidemiology and Public Health Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: While many clinical trials provide direct comparisons between biologic disease modifying antirheumatic drugs (bDMARD) and nonbiologic DMARDs (nDMARD), there is a need to better understand the effectiveness of these therapies in routine clinical practice. We evaluated changes in disease activity measures associated with changes in DMARD therapy among a large cohort of patients with RA treated in routine clinical practice.

Methods: The OM1 platform collects, links, and leverages structured and unstructured data from electronic medical records (EMR) and other sources in an ongoing and continuously updating manner. The OM1 PremiOM-RA dataset includes data on more than 200,000 patients. This analysis included patients who were treated with nDMARD at any time from January 2013 through May 2022 who had not previously received a treatment bDMARD, and who added or switched to either another nDMARD or bDMARD during the observation period (date of change in therapy is the index date). Established American College of Rheumatology endpoints for standard disease activity measures (RAPID-3, CDAI, DAS28) were used to define remission. Advanced natural language processing was used to estimate missing disease activity categories. Drug eras were defined using Observational Medical Outcomes Partnership (OMOP) definitions. Survival analyses were conducted to evaluate time to initial remission and confirmed remission, defined as 2 consecutive scores denoting remission, after index. To reduce the impact of subsequent treatment changes, follow-up was censored at 12 months. Patients who switched DMARDs or added another nDMARD after index, but subsequently switched to bDMARD before achieving remission status were considered as treatment failures.

Results: This analysis included 47,437 patients who met study inclusion criteria, had disease activity measures at baseline, and were not in remission at index date. A total of 27,128 (62.5%) patients added or switched to another nDMARD and 16,309 (37.5%) added or switched to a bDMARD. There were an average of 3.8 disease activity measures per patient and a total of 163,677 disease activity measures during the 12 month follow-up period. A larger proportion of patients in the bDMARD group achieved initial remission (20.6% versus 16.7%, p< 0.05) and confirmed remission (6.9% versus 5.1%, p< 0.05) compared to the nDMARD group. Time to remission was similar between the bDMARD group and the nDMARD group (mean (SD) 4.95 (3.18) months bDMARD v. 4.94 (3.16) months nDMARD, p=0.81), among those patients who achieved remission status and excluding patients considered treatment failures.

Conclusion: Disease activity improved with changes in DMARD therapy. The addition of bDMARDs was associated with a higher proportion of patients achieving remission within one year, but the same benefit was not seen when excluding non-responders who switched to bDMARDs. This study expands on prior observational studies in a much larger and contemporaneous cohort of patients under conditions of routine clinical practice. Further research is needed to assess the impact of specific DMARDs on time to remission.


Disclosures: Z. Su, OM1, Inc.; L. Stevens, OM1, Inc.; T. Brecht, OM1, Inc.; J. Paulus, None; S. Weiss, OM1.

To cite this abstract in AMA style:

Su Z, Stevens L, Brecht T, Paulus J, Weiss S. Impact of Change in Biologic Disease Modifying Antirheumatic Drug Therapy on Disease Activity Measures: Findings from a Large Contemporaneous Real-World Longitudinal Database of RA Patients [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/impact-of-change-in-biologic-disease-modifying-antirheumatic-drug-therapy-on-disease-activity-measures-findings-from-a-large-contemporaneous-real-world-longitudinal-database-of-ra-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-change-in-biologic-disease-modifying-antirheumatic-drug-therapy-on-disease-activity-measures-findings-from-a-large-contemporaneous-real-world-longitudinal-database-of-ra-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology